Answers are grounded in this paper and cite their sources.
Animal study finds that everolimus-coated stents reduces tissue hyperplasia in rats with gastric outlet obstruction, suggesting a viable improvement for stent patency.
Malignant gastric outlet obstruction is a severe complication of gastrointestinal malignancies, often treated with self‐expandable metallic stents (SEMSs). However, conventional SEMSs are associated with in‐stent restenosis due to granulation tissue formation. This work aims to evaluate the efficacy and safety of everolimus‐coated laser‐cut SEMS in suppressing stent‐induced tissue hyperplasia in a rat gastric outlet model. Everolimus, a next‐generation antiproliferative drug, is applied to laser‐cut SEMS using ultrasonic spray coating. The mehcanical properties, drug release profiles, and surface morphology of the stents were analyzed. In vivo, 20 rats are divided into control (uncoated laser‐cut SEMS) and experimental (everolimus‐coated laser‐cut SEMS) groups. Endoscopic and histological analyzes reveal significantly reduced granulation tissue area, submucosal fibrosis thickness, and inflammatory cell infiltration in the everolimus group compared to controls ( p < 0.05). Immunohistochemical staining demonstrates decreased smooth muscle cell proliferation and increased apoptosis in the everolimus group. The drug‐coated stents exhibit drug release over 30 days and maintain structural integrity without stent‐related adverse events. These findings suggest that everolimus‐coated laser‐cut SEMS effectively suppress stent‐induced tissue hyperplasia while preserving mechanical properties, indicating its potential as a therapeutic strategy for improving stent patency in the early stage after stent placement.
No takes yet. Share an insight, caveat, or question.
Park et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: